OakChart

Boundless Bio Inc

BOLDHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 2:47 PM ET

2.40-0.05 (-2.04%)
2026-11-11 21:01 CET
Market cap
55.73 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-55.50 USD m
Free cash flow, TTM
-57.40 USD m
EPS diluted, TTM
-2.47
P/E
-
Compare

Price

BOLD against its 20, 50 and 200-day averages
2050200earnings
1.502.002.503.0032.8M65.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BOLDclose 2.4020-day 2.4250-day 2.59200-day 1.962.4052w high

24.1% under the 52-week high of 3.16 on 24 Aug 2026. 52-week low 0.96 on 5 Feb 2026. Last 15 sessions, 10.9% high to low

Profile

BOLD
52-week range, 65% of the way up
0.963.16

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in La Jolla, CA.

Employees28
IPOMar 28, 2024
Beta0.44
ATR, 14d0.12
Rel volume0.06
Short float4.52%
Insider own23.06%
Inst own59.38%

Snapshot

6 groups

Valuation

Index-
Market Cap54.59M
Enterprise Value-8.30M
Income-55.50M
Sales0.00M
Book/sh2.67
Cash/sh2.76
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees28
IPOMar 28, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.90
P/C0.87
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio33.97
Current Ratio33.97
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.47
EPS next Y-0.75
EPS next Q-0.23
EPS this Y34.23%
EPS next Y56.14%
EPS next 5Y-
EPS past 3/5Y-8.04% -23.10%
Sales past 3/5Y- -
EPS Y/Y TTM10.69%
Sales Y/Y TTM-
EPS Q/Q62.16%
Sales Q/Q-
EarningsAug 17
EPS/Sales Surpr.-4.04% -

Ownership

Insider Own23.06%
Insider Trans9.84%
Inst Own59.38%
Inst Trans-1.32%
ROA-47.78%
ROE-64.57%
ROIC-89.91%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.70%
SMA50-7.18%
SMA20022.47%
Trades-

Technical

Shs Outstand23.11M
Shs Float17.50M
Short Float4.52%
Short Ratio5.64
Short Interest0.79M
52W High3.16 -24.14%
52W Low0.96 149.69%
Volatility3.42% 5.44%
ATR (14)0.12
RSI (14)42.34
Beta0.44
Rel Volume0.06
Avg Volume140.19K
Volume6,786

Performance

Perf Week0.00%
Perf Month-1.23%
Perf Quarter-13.51%
Perf Half Y55.84%
Perf YTD100.00%
Perf Year90.48%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom3.00
Target Price4.00
Prev Close2.45
Price2.40
Change %-2.04%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Jun 02, 2025InitiatedHH.C. WainwrightBuy$5+108.3%
May 28, 2025DowngradeLLeerink PartnersOutperform → Market Perform$3+25.0%
Dec 13, 2024DowngradeGGuggenheimBuy → Neutral
Apr 22, 2024InitiatedPPiper SandlerOverweight$20+733.3%
Apr 22, 2024InitiatedLLeerink PartnersOutperform$25+941.7%
Apr 22, 2024InitiatedGGuggenheimBuy$24+900.0%

Peers

Mkt cap
TickerCompanyMkt cap
BEAMBeam Therapeutics Inc2.66B
KRROKorro Bio Inc206.43M
WVEWave Life Sciences Inc672.55M
PRMEPrime Medicine Inc756.34M
NTLAIntellia Therapeutics Inc1.61B
ARVNArvinas Inc453.66M
ACRVAcrivon Therapeutics Inc68.57M
OLMAOlema Pharmaceuticals Inc681.61M
BDTXBlack Diamond Therapeutics Inc91.96M
CELCCelcuity Inc3.20B

Insider trading

latest 14 of 32
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
TANG KEVIN10% OwnerNov 06 '26Buy2.401,7004,0803,035,318Nov 10 05:09 PM
TANG KEVIN10% OwnerNov 10 '26Buy2.402495983,035,567Nov 10 05:09 PM
TANG KEVIN10% OwnerNov 05 '26Buy2.408,39020,1363,033,618Nov 05 06:14 PM
TANG KEVIN10% OwnerNov 03 '26Buy2.402,2555,4123,024,711Nov 05 06:14 PM
TANG KEVIN10% OwnerNov 04 '26Buy2.405171,2413,025,228Nov 05 06:14 PM
TANG KEVIN10% OwnerOct 27 '26Buy2.4010,70725,6973,022,456Oct 29 06:20 PM
TANG KEVIN10% OwnerOct 26 '26Buy2.389,60622,8623,011,749Oct 26 04:51 PM
TANG KEVIN10% OwnerOct 23 '26Buy2.386,23414,8373,002,143Oct 26 04:51 PM
TANG KEVIN10% OwnerOct 22 '26Buy2.405,80013,9202,995,909Oct 26 04:51 PM
TANG KEVIN10% OwnerOct 16 '26Buy2.34118,185276,5532,958,820Oct 20 05:49 PM
TANG KEVIN10% OwnerOct 19 '26Buy2.3331,06972,5192,989,889Oct 20 05:49 PM
TANG KEVIN10% OwnerOct 20 '26Buy2.372205212,990,109Oct 20 05:49 PM
TANG KEVIN10% OwnerAug 26 '26Sale2.9718,30054,3512,840,635Aug 28 04:16 PM
TANG KEVIN10% OwnerJul 21 '26Buy2.442,9757,2592,858,935Jul 21 07:38 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 90
  • Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today (Stocktwits) +85.71%
  • BOLD Stock Is Up 90% Here's What's Behind The Biggest Rally In Company History (Stocktwits)
  • Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement (GlobeNewswire)
  • Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire) -5.88%
  • Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting (GlobeNewswire)
  • Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026 (GlobeNewswire)
  • Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (GlobeNewswire)
  • Boundless Bio to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
  • Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's Why (Zacks)
  • Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
  • Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway (GlobeNewswire)
  • Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-17-1.060-1.060-1.0550.000.001
2026Q12026-05-08-0.600-0.577-0.6050.000.003
2025Q42026-03-09-0.580-0.520-0.5750.000.003
2025Q32025-11-05-0.620-0.583-0.6200.000.004
2025Q22025-08-05-0.700-0.650-0.7010.000.004
2025Q12025-05-09-0.710-0.735-0.7070.000.002
2024Q42025-03-27-0.740-0.757-0.7380.000.003
2024Q32024-11-07-0.740-0.748-0.7420.000.004
2024Q22024-08-12-0.770-0.800-0.7710.000.004
2024Q12024-05-13-12.270-0.640-0.6930.000.003
2026Q3---0.230--0.001
2026Q4---0.130--0.001
2027Q1---0.700--0.001
2027Q2---0.700--0.001
2027Q3---0.370--0.001
2027Q4---0.360--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-40.650--2.2230.00-
2024FY-3.850-3.830-3.8490.000.00
2025FY-2.600-2.470-40.6500.000.00
2026FY--1.710--0.00
2027FY--0.750--0.00
2028FY--1.560---
2029FY--1.340---
2030FY--1.400---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-171000.000.000.00
2026Q3S2026-06-301000.000.000.00
2026Q3S2026-06-222000.000.000.00
2026Q3S2026-05-083000.000.000.00
2026Q3S2026-03-093000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00
2026Q3S2025-11-093000.000.000.00
2026Q3S2025-11-083000.000.000.00
2026Q3S2025-11-073000.000.000.00
2026Q3S2025-11-063000.000.000.00
2026Q3S2025-11-053000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00

Estimate history

EPS, annual-1.134-2.064-2.223-3.849-2.603-2.4702
Period20212022202320242025TTM
EPS, quarterly-0.742-0.738-0.707-0.701-0.62-0.575-0.605-1.055-0.235
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000
Period20212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual22.23922.23922.23922.322.40723.109
Period20212022202320242025MRQ
Shares, quarterly22.25422.322.322.38622.38622.40722.40722.47523.109
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.951.251.090.960.940.68
Gross Profit-1.95-1.25-1.09-0.96-0.94-0.68
Selling, General and Administrative Excl. Other57.1262.3072.1853.8445.5324.62
Research and Development33.0243.5954.1841.6836.2219.28
Other Operating Expense0.000.000.000.000.000.00
Operating Income-59.06-63.55-73.27-54.80-46.47-25.30
Interest Expense0.000.000.00---
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-55.50-58.20-65.36-49.43-45.90-25.21
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-55.50-58.20-65.36-49.43-45.90-25.21
Net Income From Continuing Operations-55.50-58.20-65.36-49.43-45.90-25.21
Net Income-55.50-58.20-65.36-49.43-45.90-25.21
EPS (Recurring)-2.43-2.60-3.85-2.22-2.06-1.13
EPS (Basic, Before Extraordinaries)-2.47-2.60-3.85-2.22-2.06-1.13
EPS (Diluted)-2.47-2.60-3.85-2.22-2.06-1.13
EBITDA-57.12-62.30-72.18-53.84-45.53-24.62
Non-Operating Income (Expense)3.565.367.905.360.570.09
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense6.216.127.523.341.810.85
Shares Outstanding23.1122.4122.3022.2422.2422.24
Market Capitalization55.7355.7364.6759.99--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.101.260.280.310.310.320.320.30
Gross Profit-0.10-1.26-0.28-0.31-0.31-0.32-0.32-0.30
Selling, General and Administrative Excl. Other6.1023.1314.1913.7014.8416.7417.0217.98
Research and Development1.3412.729.459.5110.3611.9011.8213.02
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.20-24.38-14.47-14.00-15.15-17.06-17.34-18.28
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-5.36-23.69-13.55-12.88-13.88-15.68-15.76-16.45
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.36-23.69-13.55-12.88-13.88-15.68-15.76-16.45
Net Income From Continuing Operations-5.36-23.69-13.55-12.88-13.88-15.68-15.76-16.45
Net Income-5.36-23.69-13.55-12.88-13.88-15.68-15.76-16.45
EPS (Recurring)-0.23-1.06-0.60-0.58-0.62-0.70-0.71-0.74
EPS (Basic, Before Extraordinaries)-0.23-1.06-0.60-0.58-0.62-0.70-0.71-0.74
EPS (Diluted)-0.23-1.06-0.60-0.58-0.62-0.70-0.71-0.74
EBITDA-6.10-23.13-14.19-13.70-14.84-16.74-17.02-17.98
Non-Operating Income (Expense)0.840.690.921.121.271.391.581.83
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.283.221.371.331.301.691.802.01
Shares Outstanding23.1122.4822.4122.4122.3922.3922.3022.30
Market Capitalization55.7356.1924.6526.8627.5322.6133.6764.67

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments107.58152.11120.7566.7273.03
Short Term Receivables0.000.000.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets2.032.283.451.321.54
Total Current Assets109.61154.39124.2068.0474.57
Net Property, Plant & Equipment46.8851.364.587.733.10
Total Investments and Advances0.560.560.560.5335.52
Other Assets0.010.100.560.530.53
Total Assets157.06206.41129.8976.83113.72
Short Term Debt Incl. Current Port. of LT Debt3.170.002.192.340.38
Accounts Payable1.491.272.221.401.07
Other Current Liabilities7.886.864.943.992.42
Total Current Liabilities12.548.139.367.733.87
Long Term Debt45.8747.63247.62150.79147.95
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.000.010.10
Total Liabilities58.4155.77256.98158.53151.91
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity98.65150.64-127.08-81.70-38.19
Total Shareholders Equity98.65150.64-127.08-81.70-38.19
Accumulated Minority Interest0.000.000.000.000.00
Total Equity98.65150.64-127.08-81.70-38.19
Total Liabilities & Stockholders Equity157.06206.41129.8976.83113.72
Book Value Per Share4.406.76-5.71-3.67-1.72
Tangible Book Value Per Share4.406.76-5.71-3.67-1.72
Full-Time Employees286472--
Price to Book Ratio0.920.390.36--
Return on Assets-32.02-38.87-47.83-48.18-
Return on Equity-46.69-554.86---
Return on Invested Capital-40.27-32.97-41.01-66.43-22.97
Quick Ratio8.7418.9813.278.8019.28
Current Ratio8.7418.9813.278.8019.28

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-55.50-58.20-65.36-49.43-45.90-25.21
Depreciation1.951.251.090.960.940.68
Other Funds (Non Cash)14.386.825.112.424.502.12
Funds from Operations-39.17-50.12-59.16-46.06-40.46-22.41
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-17.763.46-1.68-0.800.87-0.84
Cash from Operating Activities-56.93-46.66-60.84-46.85-39.60-23.25
Capital Expenditures-0.47-0.55-2.54-0.63-1.07-2.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.270.000.000.000.000.00
Purchase or Sale of Investments75.6038.35-23.57-37.6317.20-57.25
Purchase of Investments-76.91-174.90-208.47-160.12-42.60-77.49
Sale Or Maturity of Investments152.50213.24184.90122.5059.8020.24
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities75.3937.80-26.10-38.2616.13-59.28
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock0.910.1489.8297.900.13105.53
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.910.1489.8297.900.13105.53
Proceedsfrom Stock Options0.020.1489.7697.720.00105.32
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.910.1489.8297.900.13105.53
Net Change in Cash19.37-8.722.8812.78-23.3422.99
Free Cash Flow-57.40-47.21-63.38-47.49-40.66-25.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments62.8972.6392.85107.58117.57127.15
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.701.021.772.032.592.54
Total Current Assets63.5973.6594.62109.61120.16129.69
Net Property, Plant & Equipment0.000.1045.7746.8847.9849.16
Total Investments and Advances0.000.000.560.560.560.56
Intangible Assets0.000.00----
Other Assets0.000.000.020.010.030.04
Total Assets63.5973.74140.97157.06168.72179.45
Short Term Debt Incl. Current Port. of LT Debt0.000.003.283.173.051.96
Accounts Payable0.811.052.041.491.142.29
Other Current Liabilities1.066.724.267.887.664.96
Total Current Liabilities1.877.779.5812.5411.859.21
Long Term Debt0.000.0045.0045.8746.7147.55
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.877.7754.5958.4158.5556.76
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity61.7265.9886.3898.65110.17122.69
Total Shareholders Equity61.7265.9886.3898.65110.17122.69
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity61.7265.9886.3898.65110.17122.69
Total Liabilities & Stockholders Equity63.5973.74140.97157.06168.72179.45
Book Value Per Share2.672.943.864.404.925.48
Tangible Book Value Per Share2.672.943.864.404.925.48
Full-Time Employees---28--
Price to Book Ratio0.920.650.250.240.220.16
Return on Assets-47.78-50.56-33.71-32.02-35.93-35.03
Return on Equity-64.57-67.86-50.22-46.69-44.88-42.65
Return on Invested Capital-8.69-35.91-10.32-8.92-8.85-9.21
Quick Ratio33.979.489.878.7410.1414.08
Current Ratio33.979.489.878.7410.1414.08

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-5.36-23.69-13.55-12.88-13.88-15.68
Depreciation0.101.260.280.310.310.32
Other Funds (Non Cash)-0.0410.911.871.641.531.82
Funds from Operations-5.31-11.52-11.40-10.94-12.04-13.54
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.58-9.45-3.570.831.851.71
Cash from Operating Activities-10.88-20.97-14.97-10.11-10.20-11.83
Capital Expenditures0.00-0.04-0.01-0.42-0.01-0.05
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.270.000.000.000.000.00
Purchase or Sale of Investments24.5023.1114.6013.3910.4911.34
Purchase of Investments0.00-8.39-29.41-39.10-39.51-43.66
Sale Or Maturity of Investments24.5031.5044.0052.5050.0055.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities24.7723.0714.5912.9710.4811.29
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.810.070.000.020.000.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.810.070.000.020.000.12
Proceedsfrom Stock Options0.000.000.000.020.000.12
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.810.070.000.020.000.12
Net Change in Cash14.702.17-0.392.890.28-0.42
Free Cash Flow-10.88-21.01-14.98-10.53-10.21-11.88

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.52%0.8M17.5M177.12K
2026-10-154.51%0.8M17.5M176.91K
2026-09-304.45%0.8M17.5M187.84K
2026-09-154.64%0.8M17.5M1.28M
2026-08-314.65%0.8M17.5M1.26M
2026-08-143.95%0.7M17.4M1.27M
2026-07-311.30%0.2M17.2M1.24M
2026-07-151.40%0.2M17.2M1.26M
2026-06-301.10%0.2M17.2M1.33M
2026-06-150.15%0.0M17.2M214.41K
2026-05-290.04%0.0M17.2M215.09K
2026-05-150.15%0.0M17.2M215.25K
2026-04-300.08%0.0M17.2M222.15K
2026-04-150.85%0.1M17.2M221.66K
2026-03-310.09%0.0M17.2M115.43K
2026-03-130.04%0.0M17.2M125.44K
2026-02-270.04%0.0M17.1M145.19K
2026-02-130.05%0.0M17.1M168.92K
2026-01-300.17%0.0M15.9M145.84K
2026-01-150.33%0.1M15.9M151.49K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-03EFFECTEffectiveness filing by commission orderSEC
2026-11-03424B3SEC
2026-11-02S-4/ASEC
2026-10-294Statement of changes in beneficial ownership of securities2026-10-27SEC
2026-10-26425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-26425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-10-22SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-08S-4Registration statement for securities to be issued in business combination transactionsSEC
2026-08-31DRSSEC
2026-08-28425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-288-KCurrent report2026-08-28SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-27SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-164Statement of changes in beneficial ownership of securities2026-07-14SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-29SCHEDULE 13GSEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-293Initial statement of beneficial ownership of securities2026-06-25SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1131.47K500
2026-10426.91K700
2026-090000
2026-080054.35K1
2026-07734.21K1479.68K2
2026-0666.11K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARCH Venture Management, LLC11.99%
TANG CAPITAL MANAGEMENT LLC11.39%
FMR LLC11.27%
ADAR1 Capital Management, LLC8.76%
VANGUARD CAPITAL MANAGEMENT LLC2.74%
WELLINGTON MANAGEMENT GROUP LLP2.47%
MILLENNIUM MANAGEMENT LLC2.13%
RENAISSANCE TECHNOLOGIES LLC2.10%
ACADIAN ASSET MANAGEMENT LLC1.53%
Alyeska Investment Group, L.P.1.33%

Funds

Fund% owned
Fidelity Growth Company Fund3.95%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.98%
Fidelity Growth Company K6 Fund1.00%
Fidelity Series Growth Company Fund0.85%
VANGUARD EXTENDED MARKET INDEX FUND0.68%
Ultra-Small Company Fund0.34%
Fidelity Extended Market Index Fund0.30%
iShares Micro-Cap ETF0.26%
Ultra-Small Company Market Fund0.22%
Fidelity Series Total Market Index Fund0.08%

OakChart. BOLD. Cached 15 minutes.